Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and giemsa staining. Nature. 1973;243(5405):290–3.

Article  CAS  PubMed  Google Scholar 

Goldman JM, Melo JV. Chronic myeloid leukemia–advances in biology and new approaches to treatment. N Engl J Med. 2003;349(15):1451–64.

Article  CAS  PubMed  Google Scholar 

Amarante-Mendes GP, Rana A, Datoguia TS, Hamerschlak N, Brumatti G. BCR-ABL1 tyrosine kinase complex signaling transduction: challenges to overcome resistance in chronic myeloid leukemia. Pharmaceutics. 2022;14(1):215.

Bousoik E, Montazeri Aliabadi H. Do we know jack about JAK? a closer look at JAK/STAT signaling pathway. Front Oncol. 2018;8:2018.

Article  Google Scholar 

Singh P, Kumar V, Gupta SK, Kumari G, Verma M. Combating TKI resistance in CML by inhibiting the PI3K/Akt/mTOR pathway in combination with TKIs: a review. Med Oncol. 2021;38(1):10.

Article  CAS  PubMed  Google Scholar 

Xie S, Lin H, Sun T, Arlinghaus RB. Jak2 is involved in c-Myc induction by Bcr-Abl. Oncogene. 2002;21(47):7137–46.

Article  CAS  PubMed  Google Scholar 

Chang JS, Santhanam R, Trotta R, Neviani P, Eiring AM, Briercheck E, et al. High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C/EBPalpha-driven myeloid differentiation. Blood. 2007;110(3):994–1003.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang L, Li L, Chen R, Huang X, Ye X. Understanding and monitoring chronic myeloid leukemia blast crisis: how to better manage patients. Cancer Manag Res. 2021;13:4987–5000.

Article  PubMed  PubMed Central  Google Scholar 

Craddock CF. We do still transplant CML. don’t we? Hematol. 2018;2018(1):177–84.

Article  Google Scholar 

Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376(10):917–27.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Quintás-Cardama A, Kantarjian H, Jones D, Shan J, Borthakur G, Thomas D, et al. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood. 2009;113(25):6315–21.

Article  PubMed  PubMed Central  Google Scholar 

Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108(1):28–37.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Apperley JF, Milojkovic D, Cross NCP, Hjorth-Hansen H, Hochhaus A, Kantarjian H, et al. 2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Leukemia. 2025;39(8):1797–813.

Article  PubMed  PubMed Central  Google Scholar 

Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring. Am J Hematol. 2024;99(11):2191–212.

Article  CAS  PubMed  Google Scholar 

Kantarjian H, Breccia M, Haddad FG, Hehlmann R, Issa GC, Malhotra H, et al. Management of chronic myeloid leukemia in 2025. Cancer. 2025;131(14):e35953.

Article  PubMed  PubMed Central  Google Scholar 

Bower H, Björkholm M, Dickman PW, Höglund M, Lambert PC, Andersson TM. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34(24):2851–7.

Article  CAS  PubMed  Google Scholar 

Hughes TP, Yong ASM, Ross DM. The evolution of treatment-free remission. Blood. 2025;145(9):921–30.

Article  CAS  Google Scholar 

Kantarjian HM, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre P, et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021;35(2):440–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqué C, et al. Final 5-year study results of dasision: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients Trial. J Clin Oncol. 2016;34(20):2333–40.

Article  CAS  PubMed  Google Scholar 

Sönmez Ö, Özgür Yurttaş N, İhtiyaroğlu İ, Çakır HM, Atlı Z, Elverdi T, et al. Effect of tyrosine kinase inhibitor therapy on estimated glomerular filtration rate in patients with chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2024;24(4):232–9.

Article  PubMed  Google Scholar 

Pendergast AM, Quilliam LA, Cripe LD, Bassing CH, Dai Z, Li N, et al. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell. 1993;75(1):175–85.

Article  CAS  PubMed  Google Scholar 

Shammas T, Peiris MN, Meyer AN, Donoghue DJ. BCR-ABL: The molecular mastermind behind chronic myeloid leukemia. Cytokine Growth Factor Rev. 2025;83:45–58.

Article  CAS  PubMed  Google Scholar 

Sahay S, Pannucci NL, Mahon GM, Rodriguez PL, Megjugorac NJ, Kostenko EV, et al. The RhoGEF domain of p210 Bcr-Abl activates RhoA and is required for transformation. Oncogene. 2008;27(14):2064–71.

Article  CAS  PubMed  Google Scholar 

Hantschel O, Superti-Furga G. Regulation of the c-Abl and Bcr–Abl tyrosine kinases. Nat Rev Mol Cell Biol. 2004;5(1):33–44.

Article  CAS  PubMed  Google Scholar 

Krishnan K, Tian H, Tao P, Verkhivker GM. Probing conformational landscapes and mechanisms of allosteric communication in the functional states of the ABL kinase domain using multiscale simulations and network-based mutational profiling of allosteric residue potentials. J Chem Phys. 2022;157(24):245101.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xie T, Saleh T, Rossi P, Kalodimos CG. Conformational states dynamically populated by a kinase determine its function. Science. 2020;370(6513):eabc2754.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Irgit A, Kamıs R, Sever B, Tuyun AF, Otsuka M, Fujita M, et al. Structure and dynamics of the ABL1 tyrosine kinase and its important role in chronic myeloid leukemia. Arch Pharm (Weinheim). 2025;358(5):e70005.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nagar B, Hantschel O, Young MA, Scheffzek K, Veach D, Bornmann W, et al. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell. 2003;112(6):859–71.

Article  CAS  PubMed  Google Scholar 

McWhirter JR, Galasso DL, Wang JYJA, Coiled-coil. Oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol Cell Biol. 1993;13(12):7587–95.

CAS  PubMed  PubMed Central  Google Scholar 

Preyer M, Vigneri P, Wang JYJ. Interplay between kinase domain autophosphorylation and F-actin binding domain in regulating imatinib sensitivity and nuclear import of BCR-ABL. PLoS ONE. 2011;6(2):e17020.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Poudel G, Tolland MG, Hughes TP, Pagani IS. Mechanisms of resistance and implications for treatment strategies in chronic myeloid leukaemia. Cancers (Basel). 2022;14(14):3300.

Silver RT, Woolf SH, Hehlmann R, Appelbaum FR, Anderson J, Bennett C, et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American society of hematology. Blood. 1999;94(5):1517–36.

CAS  PubMed